ArrowMark Colorado Holdings LLC Raises Stake in Entellus Medical Inc (ENTL)

ArrowMark Colorado Holdings LLC lifted its position in Entellus Medical Inc (NASDAQ:ENTL) by 28.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 986,137 shares of the medical technology company’s stock after purchasing an additional 220,961 shares during the quarter. ArrowMark Colorado Holdings LLC’s holdings in Entellus Medical were worth $24,052,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Nationwide Fund Advisors increased its holdings in shares of Entellus Medical by 61.7% in the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after purchasing an additional 2,635 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Entellus Medical by 145.1% during the third quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock worth $168,000 after acquiring an additional 5,605 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Entellus Medical by 61.7% during the second quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock worth $196,000 after acquiring an additional 4,533 shares during the last quarter. Wells Fargo & Company MN increased its stake in Entellus Medical by 74.7% during the third quarter. Wells Fargo & Company MN now owns 11,329 shares of the medical technology company’s stock worth $209,000 after acquiring an additional 4,846 shares during the last quarter. Finally, Alliancebernstein L.P. bought a new stake in Entellus Medical during the fourth quarter worth approximately $224,000. 83.44% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Several equities research analysts have weighed in on the company. BidaskClub raised Entellus Medical from a “strong sell” rating to a “sell” rating in a research note on Monday, February 5th. TheStreet raised Entellus Medical from a “d” rating to a “c-” rating in a research note on Thursday, December 14th. William Blair cut Entellus Medical from an “outperform” rating to a “market perform” rating in a research note on Friday, December 8th. ValuEngine raised Entellus Medical from a “sell” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Zacks Investment Research cut Entellus Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, January 24th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $20.33.

In other news, insider Robert S. White sold 3,471 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $24.01, for a total transaction of $83,338.71. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Thomas P. Williamson sold 2,449 shares of the company’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $24.08, for a total value of $58,971.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,623 shares of company stock worth $183,200. Insiders own 7.70% of the company’s stock.

Shares of Entellus Medical Inc (NASDAQ ENTL) opened at $24.00 on Friday. The firm has a market capitalization of $611.38, a P/E ratio of -18.75 and a beta of -0.02. Entellus Medical Inc has a 52 week low of $11.47 and a 52 week high of $25.58. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.71 and a current ratio of 1.92.

TRADEMARK VIOLATION NOTICE: “ArrowMark Colorado Holdings LLC Raises Stake in Entellus Medical Inc (ENTL)” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/03/10/arrowmark-colorado-holdings-llc-raises-stake-in-entellus-medical-inc-entl.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Want to see what other hedge funds are holding ENTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entellus Medical Inc (NASDAQ:ENTL).

Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply